While we are focused on developing the best possible cannabinoid products, we believe that improving the health and wellbeing of patients goes beyond this. That’s why we are committed to investing in research and development.
In addition to continuing to invest in science, research and development in-house, we understand that a strong partnership with clinicians and researchers is key to expanding the industry and helping people.
By prioritising research, we have the power to discover the full potential of cannabinoid medicines in preventing and treating diseases and improving lives. That’s why we partner with key universities to undertake cannabis research and support their clinical trial programs.
ANTG has listed two new THC-dominant medicinal cannabis strains on the Australian Register of Therapeutic Goods (ARTG).
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We currently have a research partnership with the Hunter Medical Research Institute, a partner of the University of Newcastle. For more information about how to become a partner please contact us.Lear more >